Olema Pharmaceuticals (NASDAQ: OLMA) net income
Olema Pharmaceuticals reported a net loss of $162.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $129.5m. Earnings per share were −$1.87.
Olema Pharmaceuticals's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$162.5m | — | — | −$1.87 |
| 2024 | −$129.5m | — | — | −$2.20 |
| 2023 | −$96.7m | — | — | −$2.14 |
| 2022 | −$104.8m | — | — | −$2.62 |
| 2021 | −$71.1m | — | — | −$1.80 |
| 2020 | −$22.1m | — | — | −$3.42 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Olema Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Olema Pharmaceuticals ranks 391st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 389th | Kyverna Therapeutics | −$161.3m | — |
| 390th | Dianthus Therapeutics | −$162.3m | −1,007.1% |
| 391st | Olema Pharmaceuticals | −$162.5m | — |
| 392nd | Nektar Therapeutics | −$164.1m | −297.1% |
| 393rd | Larimar Therapeutics | −$165.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Olema Pharmaceuticals
- How much did Olema Pharmaceuticals earn in fiscal 2025?
- Olema Pharmaceuticals reported a net loss of $162.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $129.5m.
- What are the earnings per share of Olema Pharmaceuticals?
- They were −$1.87 in fiscal 2025, compared with −$2.20 in fiscal 2024.
- Where does Olema Pharmaceuticals rank in its sector by net income?
- It ranks 391st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Olema Pharmaceuticals come from?
- From the annual report (Form 10-K) that Olema Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Olema Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Olema Pharmaceuticals: the Olema Pharmaceuticals page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.